A 52-Week, 2-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.

Trial Profile

A 52-Week, 2-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2013

At a glance

  • Drugs Cerlapirdine; Donepezil
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2012 Actual patient number 526 added as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Actual patient number 526 added as reported by ClinicalTrials.gov.
    • 10 Aug 2011 Planned end date changed from 1 Sep 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top